EarliTec Diagnostics, a leader in eye-tracking technology for early autism diagnosis and ongoing assessment, announced the appointment of Jamie Pagliaro as its new President and Chief Executive Officer, effective August 1, 2025.
Leadership Experience and Vision
Pagliaro brings nearly 30 years of experience in autism services, behavioral health, and education technology. He most recently served as Chief Operating Officer at Rethink First, where he oversaw the company’s largest division, supporting behavioral health providers, school systems, and Fortune 500 companies across a global footprint. His career has focused on scaling mission-driven innovations that improve outcomes for neurodiverse individuals and their families.
At EarliTec, Pagliaro will guide the company into its next phase of growth, expanding access to its technology and accelerating its impact in both clinical and community settings.
Advancing Early Autism Diagnosis
EarliTec’s technology platform uses patented eye-tracking methods and visual attention biomarkers to provide objective, quantifiable insights into a child’s development. This approach enables earlier identification of autism and offers ongoing assessment to monitor progress throughout treatment.
With new leadership, the company plans to expand access to this innovative platform, bringing earlier diagnosis and ongoing monitoring to more families and healthcare providers—especially in underserved communities.
Recognizing Past Leadership
The company also announced the retirement of Tom Ressemann, who led EarliTec from its early development through FDA approval and into real-world adoption. Under his leadership, EarliTec moved from concept to clinically validated technology now in use across multiple settings.
About EarliTec Diagnostics
EarliTec Diagnostics, Inc. is a health technology company transforming the standard of care for autism and other neurodevelopmental conditions. Through FDA-authorized eye-tracking technology and visual attention biomarkers, EarliTec provides objective, rapid assessments of social, verbal, and non-verbal development in children as young as 16 months. The platform supports both early diagnosis and ongoing assessment, enabling more timely, personalized, and effective interventions.
